Nucleoside Inhibitors of Hepatitis C Virus NS5B Polymerase: A Systematic Review

Author(s): Yuanchao Xie, Comfort Alicha Ogah, Xiangrui Jiang, Jianfeng Li, Jingshan Shen

Journal Name: Current Drug Targets

Volume 17 , Issue 13 , 2016


  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Nowadays, a large number of people in the world are suffering from chronic Hepatitis C. HCV NS5B polymerase conserved across the identified 7 HCV genotypes is considered to be the most promising target in combating HCV. During the past decade, significant progress has been made in the discovery of novel nucleoside HCV NS5B polymerase inhibitors. A potent anti-HCV drug, sofosbuvir with high cure rates has been approved. Besides, quite a few nucleoside anti-HCV agents are being evaluated in clinical trials. The purpose of this review is to present recent progress in the development of nucleoside HCV NS5B polymerase inhibitors, focusing on lead compounds that hold great promise for medicinal use and their structure-activity relationships (SARs) in order to provide guidance for future drug design and discovery.

Keywords: Hepatitis C virus, inhibitor, nucleoside, NS5B polymerase, prodrug, SAR.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 17
ISSUE: 13
Year: 2016
Published on: 01 September, 2016
Page: [1560 - 1576]
Pages: 17
DOI: 10.2174/1389450117666151209123751
Price: $65

Article Metrics

PDF: 52
HTML: 5
EPUB: 2